Ellis Andrea's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Jul 13, 2026
- Accession no.
- 0001470831-26-000709
- Filed
- Jul 13, 2026, 4:41 PM ET
- Trade date
- Jul 9, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.44M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ellis AndreaCIK 0001877680 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Common Stock | MOption exerciseAcquired | +17,167 | $16.75 | +$287,547.25 | 39,746 | Direct | |
| Jul 9, 2026 | Common Stock | SSaleDisposed | −17,167 | $84.00 | −$1,442,028 | 22,579 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Common Stock | MOption exerciseDisposed | −17,167 | $0.00 | $0 | 17,167 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.